Occupational Asthma Reference
Munoz X, Culebras M, Cruz MJ, Morell F,
Occupational asthma related to aescin inhalation,
Ann Allergy Asthma Immunol,
Keywords: Barcelona, Spain, Challenge, Aescin, pharmaceutical, case report, Aesculus hippocastanum, horse chestnut, nsbr, peak flow
BACKGROUND: More than 400 agents are recognized as causes of occupational asthma, a work-related disease that can be induced by an immunologic or a nonimmunologic mechanism.
OBJECTIVE: To describe a 57-year-old man employed in the pharmaceutical industry who developed bronchial asthma while working with products such as Plantago ovata and aescin, an active ingredient with anti-inflammatory and venotonic properties.
METHODS: Various tests were performed, including radiography, total serum IgE titer measurements, skin tests against common pneumoallergens and Plantago species, pulmonary function studies, a methacholine test, and specific inhalation challenge with P. ovata and aescin.
RESULTS: The results of these tests, including specific inhalation challenge, confirmed the diagnosis of occupational asthma due to aescin exposure, whereas the results of specific challenge with P. ovata, a known cause of occupational asthma, were negative.
CONCLUSIONS: Aescin may represent a new causative agent of occupational asthma in personnel working in the pharmaceutical industry. The mechanism by which aescin can produce asthma is unknown, but analysis of the characteristics of our patient suggests a non-IgE immunologic mechanism, although an irritative mechanism secondary to long-term low-level exposure to aescin, a possible irritant, cannot be ruled out.
Full text of this reference not available
Please Log In or Register to add the full text to this reference
Registered users of this website have associated this reference with the
following questions. This association is not a part of the BOHRF occupational
Please Log In or Register to put forward this reference as evidence to a question.
Positive challenge, positive PEF, 20 year latent interval.
Please sign in or register to add your thoughts.